Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries (NYSE:LLY)

INDIANAPOLIS and INGELHEIM, Germany, Oct. 29, 2014 /PRNewswire/ -- In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90 percent of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance.

The changes will be implemented starting January 1, 2015.

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries (NYSE:LLY)